Medical startup Medii said on April 23 that it has built a physician collaboration system with the Japanese Society of Child Neurology to support the safe and appropriate use of Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene…
To read the full story
Related Article
- DMD Gene Therapy Elevidys Hits Japan Market at Record Price
February 20, 2026
BUSINESS
- AbbVie Japan Says Sales-Doubling Plan on Track as Revenue Climbs 13.5%
June 3, 2026
- FunPep, Crafton Join Forces on Therapeutic mRNA Vaccines
June 3, 2026
- Shionogi’s Xocova Scores US FDA Nod for COVID-19 PEP
June 3, 2026
- J&J’s Tremfya Now Available for Self-Injection in IBD
June 2, 2026
- J&J Taps Leading Cancer Centers to Bolster Japan Trial Environment
June 2, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





